2015 News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
05/18/15StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 2015 Marcum MicroCap Conference. Management is scheduled to speak at 1:30 p.m. Eastern Daylight Time on Thursday, May 28, at The Grand Hyatt New York Hotel, in the Imperial room, located at 109 E 42nd Street in New York ... 
Printer Friendly Version
05/14/15StemCells, Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study
Sensory gains demonstrate the clinical effect of HuCNS–SC® transplantation Results hold promise for Phase II PathwayTM cervical spinal cord injury study NEWARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system, announced today that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the ... 
Printer Friendly Version
05/05/15StemCells, Inc. Reports First Quarter 2015 Financial Results and Provides Business Update
Conference Call to be Hosted May 5, 2015, at 4:30PM EDT (1:30 PM PDT) NEWARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the first quarter 2015. "StemCells, Inc. continues to make great progress," said Martin McGlynn, CEO of StemCells, Inc. "We have completed the en... 
Printer Friendly Version
04/30/15StemCells, Inc. Announces Webcast to Discuss First Quarter 2015 Financial Results
NEWARK, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter 2015, after the market close on Tuesday, May 5. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Time ... 
Printer Friendly Version
04/29/15StemCells, Inc. Announces Closing of $25 Million Public Offering
NEWARK, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced offering of common stock and warrants. The Company sold a total of 35,715,000 shares and warrants to acquire 26,786,250 shares of common stock at a public offering price of $0.70 per unit for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The Company also issued warrants to purchase an a... 
Printer Friendly Version
04/27/15StemCells, Inc. to Participate at the Inaugural World Medical Innovation Forum
CEO Martin McGlynn Will Participate on the "Regeneration, Cell Therapy, and Neurocare: Products? Delivery?" Panel NEWARK, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will participate on a panel moderated by Alice Park, writer for TIME Magazine, at the inaugural World Medical Innovation Forum to be held in Boston, April 27-29, 2015. The expert panel members will discuss central nervous system therapies that... 
Printer Friendly Version
04/24/15StemCells, Inc. Announces Pricing of Public Offering to Raise $25 Million
NEWARK, Calif., April 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance. The Company expects to recei... 
Printer Friendly Version
04/23/15StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, includi... 
Printer Friendly Version
04/16/15StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury
Proof-of-Concept Study Designed to Measure Improvement in Motor Function NEWARK, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system with high unmet medical need, announced today that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway® Study. The first cohort is an open-label dose escalation arm to determi... 
Printer Friendly Version
04/07/15StemCells, Inc. to Participate at the 14th Annual Needham Healthcare Conference
CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., April 7, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will make a presentation on the Company's programs and operations at the 14th Annual Needham Healthcare Conference. Management is scheduled to speak at 3:40 p.m. Eastern Daylight Time on Wednesday, April 15, at The Westin NY Grand Central Hotel located at 212 E 42n... 
Printer Friendly Version
03/24/15StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
NEWARK, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality as... 
Printer Friendly Version
03/16/15StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Conference Call to be Hosted March 16, 2015 at 4:30 p.m. EDT (1:30 PM PDT) NEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014. "We achieved three significant clinical translation milestones in 2014: the completi... 
Printer Friendly Version
03/10/15StemCells, Inc. to Participate at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference. Management is scheduled to speak at 10:35 a.m. Eastern Daylight Time on Thursday, March 19, at The University Club located at 1 West 54th Street in NYC. ... 
Printer Friendly Version
03/09/15StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2014 Financial Results
NEWARK, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market close on Monday, March 16. StemCells will host a conference call and webcast to discuss its results and an update on its business ... 
Printer Friendly Version
02/05/15Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference
NEWARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on... 
Printer Friendly Version
02/02/15StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17th Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City. A live webcast of the presentations will be available through the... 
Printer Friendly Version
01/26/15StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. January 26, 2015 Dear Fellow Shareholders: Over the past year, StemCells, Inc. has made substantial progress. We completed enrollment and dosing in our Phase I/II clinical trials in two major indicat... 
Printer Friendly Version